Estiva 600mg (Efavirenz)

DESCRIPTION

Estiva tablet in co administration with other drugs to treat the infection caused by HIV. Estiva will not curable or preventable HIV/AIDS. Estiva suppress the HIV replication of virus cell and despite the destruction of the immune system.

Estiva may help to delay the problems arises from AIDS/HIV diseases. The medicine allowed purchasing only with doctors prescription.

INDICATION

In adult and childerns 3 months old / weight of 3.5kg, Estiva is used by combination with other antiretroviral regimens for the treatment of HIV-1 type(human immunodeficiency virus).

MECHANISM OF ACTION

Estiva is an non nucleoside reverse transcriptase inhibitor that fight against HIV-1 and stops HIV-1 replication and RNA & DNA dependent polymerase activities.

ADME PROPERTIES

ABSORPTION

Efavirenz ( Estiva ) , bioavailabilty is 42% and Peak plasma concentration is 3-5hr.

DISTRIBUTION

Efavirenz ( Estiva ) is distributed in CSF, enter into breast milk and protein bound is 99%

METABOLISM

Efavirenz ( Estiva ) mainly metabolized inCYP3A4 and CYP2B and isoenzyme to inactive hydroxyl metabolite.

ELIMINATION

In Estiva excreted via urine(14-34%) and faeces is 16-61% while terminal half life is 52-76hr(single dose) and 40-55hr (multiple dose).

DOSAGE MANAGEMENT

Estiva co administration with other antiretrovirals dosage of 600mg once daily (capsule/tablet) and solution of 720mg once daily. Estiva should administrate with empty stomach, preferably bedtime.

PRECAUTION

Monitor the patients with these problems and inform the healthcare providers: cholesterol and triglycerides. Lfts in patients with history of hepatitis b and/or c.hepatic function use.

Convulsions use with caution in patients with history of seizures. Cns symptoms redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement. Liver enzymes in patients with suspected past of hepatitis b or c infection and liver toxicity.

Immune reconstitution syndrome. Lipids increases in total cholesterol and triglycerides have been checked, monotherapy resistant virus may emerge rapidly. Psychiatric symptoms psychiatric disorders may be at greater risk. Some occasional reports of death by suicide, delusions, and psychosis-like behavior. Skin rash reported in 26% of adults and 46% of children. Over dosage symptoms increased cns symptoms, involuntary muscle contractions.

DRUG INTERACTION

Estiva with psychoactive drugs leads to additive CNS effects and change plasma warfarin concentrations with warfarin. Interaction with HIV integrase inhibitors (dolutegravir), other HIV NNRTIs ( etravirine), HMG-CoA reductase inhibitors ( simvastatin) reduce plasma concentration Estiva with voriconazole ,plasma concentrations of efavirenz is high and voriconazole is decreased when given continuity. Serious, life-threatening events (e.g. cardiac arrhythmias, respiratory depression) may produce when Estiva given with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil or ergot alkaloids (ergotamine)

CONTRAINDICATIONS

Concurrent use with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil or ergot alkaloids (ergotamine) causes hypersensitivity, severe hepatic impairment, lactation in patient.

PREGNANCY

Efavirenz has category D: Based on adverse effects by investigation and experience studies in humans a positive identification of human fetal risk is reported.
STORAGE

Estiva store in a closed container at room temperature. Kept away the medicine ( Estiva ) from heat, moisture, and direct light. Keep from freezing and reach of children. Do not uses after expiry date Ask your consultant about how should dispose of any medicine you do not use.

MISSED DOSE

If missed to take a dose ,leave the dose and take your next dose at the normal time or take it as soon as you remember and take your next dose at the normal time. Do not have the extra dose to make up for a missed dose. Please consult with the doctor.